LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated initial progress in its research collaboration with Biogen Idec, M.A. ("Biogen Idec") to discover microRNAs as biomarkers for multiple sclerosis ("MS") and has received a milestone payment.
Regulus has developed a highly reproducible, proprietary platform for extracting, profiling, and analyzing microRNAs from small volumes of serum. Under its collaboration with Biogen Idec, Regulus applied this platform to profile over 400 serum samples from MS patients and compared these samples against those from healthy volunteers in the largest known MS serum profiling experiment performed to date. The results of this large and successful experiment have provided the foundation for identifying potential biomarker signatures for patients with MS. Based on the initial progress, Regulus and Biogen Idec will now work on the next phase of the research collaboration to validate further the microRNA biomarker signatures in patients with relapse-remitting MS, the most common form of the disease.
"We are very excited about our early success in this collaboration and are hopeful that our efforts advance Biogen Idec's work in treating MS," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Further, we believe that achievement of this milestone assigns significant value to our proprietary technology and demonstrates the potential of our emerging biomarkers platform to support our microRNA therapeutic pipeline." Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse. &
|SOURCE Regulus Therapeutics Inc.|
Copyright©2012 PR Newswire.
All rights reserved